Johnson & Johnson (JNJ) announced Phase 2b data from two studies evaluating JNJ-4804, in patients with moderately to severely active ulcerative colitis or Crohn's disease that is refractory to systemic therapies
Context
Johnson & Johnson's announcement of Phase 2b data for JNJ-4804 is significant as it evaluates a potential treatment for difficult cases of ulcerative colitis and Crohn's disease. Positive data could bolster JNJ's standing in the pharmaceutical sector and attract investor interest, enhancing the outlook for future revenues. Investors will be watching closely for market reactions based on efficacy and safety profiles of the treatment.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#JOHNSON & JOHNSON#JNJ.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#US EQUITIES